A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
To determine:
- Anti-tumor activity of IPI-504 in 2 groups of subjects with hormone resistant prostate
cancer.
- Group A - subjects who have not previously received chemotherapy
- Group B - sujects who have received prior chemotherapy or could not tolerate
chemotherapy.
- Clinical response will be determined by PSA and radiological response